Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis

Biosimilars help push growth in the Sandoz unit

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 3Q10

3Q10 Revenues: $12.6 billion (+13%)

3Q10 Earnings: $2.3 billion (+10%)

YTD Revenues: $36.4 billion (+16%)

YTD Earnings: $7.7 billion (+26%)

Comments: Branded pharma sales were up 6% to $7.6 billion in the quarter, while generic sales (the Sandoz unit) posted 18% growth to $2.2 billion and Vaccines/Diagnostics posted $600 million (+21%) in sales. Consumer Health added $1.6 billion (+9%). During the quarter, the company acquired an additional 52% of Alcon, consolidating that company and adding $617 million in sales for the quarter. New and recent launches comprised 20% of net sales ($2.3 billion) in pharma. In the Sandoz unit, biosimilars drove growth; generic Lovenox, launched in the quarter, posted $292 million in revenues.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics